SCHEMBL21044112

SCHEMBL21044112

N#Cc1cncc(-c2ccc(N)nc2)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.59
MAP4K4 O95819 3/20 0.56
CYP11B2 P19099 4/20 0.53
CYP11B1 P15538 3/20 0.53
USP7 Q93009 2/20 0.47
PIK3CG P48736 1/20 0.44
DYRK1A Q13627 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
CYP1A2 P05177 1/20 0.43
KCNH2 Q12809 1/20 0.43
MINK1 Q8N4C8 1/20 0.43
TNIK Q9UKE5 1/20 0.43
INPPL1 O15357 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044264 0.81 CYP11B2 (0.57) MAP4K4CYP11B2CYP11B1USP7PIK3CG
SCHEMBL30725703 0.81 CYP11B2 (0.57) MAP4K4CYP11B2CYP11B1USP7PIK3CG
SCHEMBL15156799 0.80 PIK3CD (0.59) PIK3CDMAP4K4CYP11B2CYP1A2KCNH2
SCHEMBL5562910 0.80 MAP4K4 (0.62) PIK3CDMAP4K4CYP11B2CYP11B1CYP1A2
SCHEMBL2983844 0.80 CYP11B2 (0.61) MAP4K4CYP11B2CYP11B1PIK3CGPRMT5
SCHEMBL17116617 0.78 CYP11B2 (0.62) MAP4K4CYP11B2CYP11B1PIK3CGPRMT5
SCHEMBL17116663 0.77 CYP11B1 (0.49) MAP4K4CYP11B2CYP11B1USP7PRMT5
SCHEMBL18223993 0.76 CYP11B2 (0.52) PIK3CDMAP4K4CYP11B2CYP11B1PIK3CG
SCHEMBL17116680 0.76 CYP11B2 (0.58) MAP4K4CYP11B2CYP11B1PIK3CGPRMT5
SCHEMBL21044254 0.74 CYP11B2 (0.70) MAP4K4CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 PIK3CD 2075/4885MAP4K4 1996/4885CYP11B2 1869/4885
US-20210002269-A1 COMPOUNDS UGT1A1, CYP1A1, CYP19A1 PIK3CD 3859/4885MAP4K4 3209/4885CYP11B2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.